Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.57 |
| ▸ | MTOR | P42345 | 7/20 | 0.57 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 7/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LGMN | Q99538 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1735480 | 0.79 | CNR2 (0.55) | CNR2POLBLMNAMAPTKDM4E | |
| SCHEMBL12057439 | 0.79 | CNR2 (0.47) | PIK3CAPIK3CDPIK3CBCNR2POLB | |
| SCHEMBL12093777 | 0.79 | MAPT (0.51) | PIK3CAMTORPIK3R1CNR2POLB | |
| SCHEMBL16427595 | 0.79 | CNR2 (0.47) | CNR2POLBLMNAMAPTKDM4E | |
| SCHEMBL521049 | 0.79 | PIK3CA (0.56) | PIK3CAMTORPIK3R1PIK3CDDHFR | |
| SCHEMBL2941802 | 0.78 | MAPT (0.48) | PIK3CADHFRPOLBLMNAMAPT | |
| Hydrochloric Acid SCHEMBL1735765 | 0.78 | CNR2 (0.46) | PIK3CAPIK3CDPIK3CBCNR2POLB | |
| SCHEMBL12991818 | 0.77 | LGMN (0.49) | PIK3CAMTORPIK3R1PIK3CDPIK3CB | |
| SCHEMBL359690 | 0.76 | LGMN (0.56) | PIK3CAMTORPIK3R1PIK3CDPIK3CB | |
| SCHEMBL2711385 | 0.76 | LGMN (0.47) | PIK3CAMTORPIK3R1DHFRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818641-B | Pyridazine-3-formamide compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| WO-2022032484-A1 | PYRIDAZINE-3-FORMAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 北京诺诚健华医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
| CN-110818641-A | Pyridazine-3-formamide compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2696683-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | Alzheimer's Institute of America, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012142329-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | MYREXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| US-7750019-B2 | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same | KOWA COMPANY, LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| EP-2055703-A1 | NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(PYRIDYLMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL COMPRISING THE COMPOUND | Kowa Company. Ltd. (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20090054474-A1 | Novel pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same | KOWA COMPANY, LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| CN-101068797-A | Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof | MITSUBISHI PHARMA CORP (JP) | 2007-11-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054474-A1 | Novel pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same | CETP, TYMP, MTTP | PIK3CA 3170/4885MTOR 2141/4885PIK3R1 2625/4885 |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | CSNK1G1, PRKCE, PHKG1 | PIK3CA 226/4885MTOR 349/4885PIK3R1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.